| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥65.36 |
| 52 Week High | CN¥77.78 |
| 52 Week Low | CN¥51.01 |
| Beta | 0.065 |
| 1 Month Change | -8.97% |
| 3 Month Change | -0.98% |
| 1 Year Change | 4.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301096 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -3.1% | -2.9% | -1.5% |
| 1Y | 4.1% | -32.5% | -11.3% |
Return vs Industry: 301096 exceeded the CN Life Sciences industry which returned -32.5% over the past year.
Return vs Market: 301096 exceeded the CN Market which returned -11.3% over the past year.
Price Volatility
| 301096 volatility | |
|---|---|
| 301096 Average Weekly Movement | 5.0% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 301096 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301096's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,747 | Jinfang Lou | www.hzbio-s.com |
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Fundamentals Summary
| 301096 fundamental statistics | |
|---|---|
| Market cap | CN¥7.07b |
| Earnings (TTM) | CN¥286.72m |
| Revenue (TTM) | CN¥1.07b |
23.9x
P/E Ratio6.4x
P/S RatioIs 301096 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301096 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.07b |
| Cost of Revenue | CN¥365.57m |
| Gross Profit | CN¥706.66m |
| Other Expenses | CN¥419.94m |
| Earnings | CN¥286.72m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.65 |
| Gross Margin | 65.91% |
| Net Profit Margin | 26.74% |
| Debt/Equity Ratio | 23.1% |
How did 301096 perform over the long term?
See historical performance and comparison